Department of Medical Oncology, Università Campus Bio-Medico di Roma, Rome, Italy.
Department of Translational Research and New Technologies in Medicine and Surge, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy.
Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004.
Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial.
Pts enrolled in TRIBE trial were included. TRIBE is a multicentre phase III trial randomizing unresectable and previously untreated mCRC pts to receive FOLFOXIRI or FOLFIRI plus bevacizumab. A cut-off value of 3 was adopted to discriminate pts with low (NLR < 3) versus high (NLR ≥ 3) NLR, as primary analysis. As secondary analysis, NLR was treated as an ordinal variable with three levels based on terciles distribution.
NLR at baseline was available for 413 patients. After multiple imputation at univariate analysis, patients with high NLR had significantly shorter progression-free survival (PFS) [hazard ratio (HR) 1.27 (95% CI 1.05-1.55), P = 0.017] and overall survival (OS) [HR 1.56 (95% CI 1.25-1.95), P < 0.001] than patients with low NLR. In the multivariable model, NLR retained a significant association with OS [HR 1.44 (95% CI 1.14-1.82), P = 0.014] but not with PFS [HR 1.18 (95% CI 0.95-1.46), P = 0.375]. No interaction effect between treatment arm and NLR was evident in terms of PFS (P for interaction = 0.536) or OS (P for interaction = 0.831). Patients with low [HR 0.84 (95% CI 0.64-1.08)] and high [HR 0.73 (95% CI 0.54-0.97)] NLR achieved similar PFS benefit from the triplet and consistent results were obtained in terms of OS [HR 0.83 (95% CI 0.62-1.12) for low NLR; HR 0.82 (95% CI 0.59-1.12) for high NLR].
This study confirmed the prognostic role of NLR in mCRC pts treated with bevacizumab plus chemotherapy in the first line, showing the worse prognosis of pts with high NLR. The advantage of the triplet is independent of NLR at baseline.
中性粒细胞/淋巴细胞比值(NLR)定义为绝对中性粒细胞计数除以绝对淋巴细胞计数,已在多种肿瘤疾病中被报道为不良预后因素,但关于不可切除转移性结直肠癌(mCRC)患者的相关数据有限。本研究的目的是评估 NLR 在 TRIBE 试验中的预后和预测作用。
纳入 TRIBE 试验中的患者。TRIBE 是一项多中心 III 期试验,将不可切除和未经治疗的 mCRC 患者随机分为接受 FOLFOXIRI 或 FOLFIRI 联合贝伐珠单抗治疗。采用 3 作为分界值,将 NLR 较低(NLR<3)和较高(NLR≥3)的患者作为主要分析。作为次要分析,NLR 作为一个有序变量,根据三分位数分布分为三个水平。
基线时 413 例患者可评估 NLR。单变量分析时,通过多重插补后,NLR 较高的患者无进展生存期(PFS)[风险比(HR)1.27(95%CI 1.05-1.55),P=0.017]和总生存期(OS)[HR 1.56(95%CI 1.25-1.95),P<0.001]明显短于 NLR 较低的患者。多变量模型中,NLR 与 OS 仍显著相关[HR 1.44(95%CI 1.14-1.82),P=0.014],但与 PFS 无关[HR 1.18(95%CI 0.95-1.46),P=0.375]。在 PFS(P 交互=0.536)和 OS(P 交互=0.831)方面,治疗组和 NLR 之间无交互作用。NLR 较低[HR 0.84(95%CI 0.64-1.08)]和较高[HR 0.73(95%CI 0.54-0.97)]的患者从三联治疗中获得相似的 PFS 获益,OS 也有一致的结果[NLR 较低的 HR 0.83(95%CI 0.62-1.12);NLR 较高的 HR 0.82(95%CI 0.59-1.12)]。
本研究证实 NLR 在接受贝伐珠单抗联合化疗一线治疗的 mCRC 患者中具有预后作用,表明 NLR 较高的患者预后更差。三联治疗的优势独立于基线时的 NLR。